- Condition: Multiple Sclerosis
Interventions: Drug: PR Fampridine; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Rebif; Other: other disease modifying therapies (DMT)
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Recruiting - verified May 2012 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Intervention: Procedure: Overnight closed-loop insulin delivery
Sponsors: University of Cambridge; Daniela Elleri; Cambridge University Hospitals NHS Foundation Trust
Not yet recruiting - verified March 2012 - Conditions: Multiple Sclerosis; Chronic Cerebrospinal Venous Insufficiency
Intervention: Procedure: percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency
Sponsors: University of Stirling; University of Stirling
Not yet recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Pro insulin peptide; Drug: Pro insulin peptide; Drug: Saline
Sponsors: Cardiff University; Cardiff University; Diabetes Vaccine Development Centre; Juvenile Diabetes Research Foundation
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Intervention: Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
Sponsors: Northumbria University; Northumbria University; Diabetes UK
Recruiting - verified February 2012 - Condition: Idiopathic Thrombocytopenic Purpura
Interventions: Drug: 10-mg dose of E5501 2G tablet; Drug: 10-mg dose of E5501 cyclodextrin oral solution; Drug: 10-mg dose of E5501-P21% powder; Drug: 10-mg dose of E5501 lipid-based oral
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Device: The Imperial College Closed-Loop Insulin Delivery System
Sponsors: Imperial College London; Imperial College London
Recruiting - verified February 2012 - Conditions: Multiple Sclerosis; Fatigue
Interventions: Other: Cognitive behavioural therapy based self help; Other: Treatment as usual
Sponsors: University of Edinburgh; University of Edinburgh
Not yet recruiting - verified January 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin detemir; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Interventions: Drug: MOR103; Drug: MOR103; Drug: MOR103
Sponsors: MorphoSys AG; MorphoSys AG
Recruiting - verified March 2012 - Conditions: Multiple Sclerosis; Pregnancy
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Hookworm larvae; Biological: Placebo
Sponsors: University of Nottingham; University of Nottingham; National Multiple Sclerosis Society
Not yet recruiting - verified November 2011 - Condition: Type 1 Diabetes
Interventions: Drug: Diazoxide; Drug: Placebo
Sponsors: University of Dundee; University of Dundee; Juvenile Diabetes Research Foundation
Not yet recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Optic Neuritis; Multiple Sclerosis
Interventions: Drug: Phenytoin; Drug: Placebo
Sponsors: University College, London; University College, London; National Multiple Sclerosis Society; Multiple Sclerosis Society of Great Britain and Northern Ireland
Not yet recruiting - verified October 2011 - Condition: Purpura, Thrombocytopaenic, Idiopathic
Interventions: Drug: Belimumab; Drug: Normal saline placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Device: ACCU-CHEK AVIVA EXPERT MMOL/L (651); Other: No Intervention
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified August 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Other: Closed-loop; Other: Conventional insulin pump delivery
Sponsors: University of Cambridge; University of Cambridge; Diabetes UK
Not yet recruiting - verified September 2011 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin glargine; Drug: Insulin detemir
Sponsors: Buckinghamshire Healthcare NHS Trust; Buckinghamshire Healthcare NHS Trust; Novo Nordisk
Recruiting - verified November 2011 - Conditions: Osteoarthritis; Avascular Necrosis; Rheumatoid Arthritis; Developmental Dysplasia of the Hip
Intervention:
Sponsors: Wirral University Teaching Hospital NHS Trust; Hussain Kazi
Not yet recruiting - verified September 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Revamilast; Drug: Revamilast; Drug: Revamilast; Drug: Placebo Comparator
Sponsors: Glenmark Pharmaceuticals Ltd. India; Glenmark Pharmaceuticals Ltd. India; Glenmark Pharmaceuticals SA
Recruiting - verified December 2011 - Condition: Multiple Sclerosis
Intervention: Radiation: [18F]PBR111
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel FormationCondition: Type 1 Diabetes
Intervention: Device: Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)
Sponsors: University of Dundee; University of Dundee
Not yet recruiting - verified September 2011 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo to Secukinumab (AIN457); Biological: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Interventions: Other: Standard Physiotherapy Exercises; Other: Core Stability Training; Other: Relaxation
Sponsors: University of Plymouth; University of Plymouth
Recruiting - verified August 2011 - Condition: Acute Rheumatoid Arthritis
Intervention: Drug: s.c. injections of bovine intestinal Alkaline Phosphatase
Sponsors: Alloksys Life Sciences B.V.; Alloksys Life Sciences B.V.; Aix Scientifics
Recruiting - verified August 2011 - Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Elan Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Vasculitis; Microscopic Polyangiitis; Granulomatosis With Polyangiitis; Wegener's
Intervention: Drug: Alemtuzumab
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust
Recruiting - verified July 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Central Neuropathic Pain; Multiple Sclerosis
Intervention: Drug: AVP-923
Sponsors: Avanir Pharmaceuticals; Avanir Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Polymyalgia Rheumatica; Inflammatory Diseases
Interventions: Drug: AIN457; Drug: ACZ885 (canakinumab); Drug: Prednisone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: CDP6038
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Adrenal Failure
Intervention: Drug: depot tetracosactide
Sponsors: Newcastle University; Newcastle University
Recruiting - verified June 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Sifalimumab; Drug: Sifalimumab; Drug: Sifalimumab; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified January 2012 - Condition: Multiple Sclerosis
Intervention: Drug: fingolimod
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Adalimumab and placebo of fostamatinib; Drug: Placebo of fostamatinib, fostamatinib, and placebo injections
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib; Drug: Fostamatinib; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Part 1: Etoricoxib 60 mg; Drug: Part 1: Etoricoxib 90 mg; Drug: Part 2: Etoricoxib 60 mg; Drug: Part 2: Etoricoxib 90 mg; Drug: Part 1: Placebo to Etoricoxib 60 mg; Drug: Part 1: Placebo to Etoricoxib 90 mg; Drug: Part 2: Placebo to Etoricoxib 60 mg; Drug: Part 2: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Conditions: Atherosclerosis; Systemic Lupus Erythematosus
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: Imperial College London; Imperial College London
Recruiting - verified August 2011 - Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Other: AMG 531
Sponsors: Amgen; Amgen
Recruiting - verified November 2011 - Conditions: Osteoarthritis; Rheumatoid Arthritis
Interventions: Procedure: Minimally Invasive Anterior Approach; Procedure: Standard postero-lateral approach
Sponsors: Medacta International SA; Medacta International SA
Recruiting - verified January 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: ATX-MS-1467
Sponsors: Apitope Technology (Bristol) Ltd.; Apitope Technology (Bristol) Ltd.; Aptiv Solutions (UK); ClinStar Europe LLC (Russia)
Recruiting - verified February 2012 - Conditions: Rheumatoid Arthritis; Osteoarthritis; Post-traumatic Arthritis; Avascular Necrosis; Traumatic Femoral Fractures; Congenital Hip Dysplasia
Intervention: Device: DePuy Proxima™ Hip
Sponsors: DePuy International; DePuy International
Recruiting - verified February 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Otelixizumab; Drug: Matching placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis
Interventions: Device: Vanguard CR; Device: AGC knee
Sponsors: Biomet, Inc.; Biomet, Inc.; Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK); Biomet U.K. Ltd.
Recruiting - verified December 2011 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified March 2012 - Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis
Intervention: Drug: anti-TNF therapy (etanercept or adalimumab)
Sponsors: Imperial College London; Imperial College London
Recruiting - verified September 2011 - Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified July 2011 - Conditions: Relapsing-remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
Intervention:
Sponsors: Imperial College London; Imperial College London; Medical Research Council; Imperial College Healthcare NHS Trust; University College, London; Queen Mary University of London; GlaxoSmithKline; University of Cambridge
Recruiting - verified April 2012 - Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Merck
Recruiting - verified April 2012 - Condition: Giant Cell Arteritis
Interventions: Procedure: Ultrasound of temporal and axillary arteries; Procedure: Temporal artery biopsy
Sponsors: University of Oxford; University of Oxford; University of Sheffield; Southend University Hospital; Nuffield Orthopaedic Centre NHS Trust; John Radcliffe Hospital; The Leeds Teaching Hospitals NHS Trust; University of Bristol; London School of Hygiene and Tropical Medicine; Medical Center for Rheumatology Berlin-Buch
Recruiting - verified January 2012 - Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Urinary Catheterization; Multiple Sclerosis
Interventions: Device: LoFric Primo + Anticholinergic medication; Drug: Anticholinergic medication
Sponsors: Astra Tech AB; Astra Tech AB
Recruiting - verified August 2011 - Conditions: Purpura, Thrombocytopenic, Idiopathic; Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Type 1 Diabetes; Type 2 Diabetes
Intervention: Biological: Autologous CD34+ stem cells
Sponsors: Imperial College London; Imperial College London
Recruiting - verified July 2011 - Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Osteoarthritis; Avascular Necrosis; Traumatic Arthritis; Rheumatoid Arthritis
Intervention: Procedure: metal on metal hip arthroplasty
Sponsors: Biomet, Inc.; Biomet, Inc.; Biomet U.K. Ltd.
Not yet recruiting - verified May 2012 - Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: IGIV3I Grifols
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified January 2012 - Condition: Multiple Sclerosis
Interventions: Biological: Live Hookworm Larvae; Other: Histamine
Sponsors: University of Nottingham; University of Nottingham
Not yet recruiting - verified November 2011 - Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis
Interventions: Drug: Celecoxib; Drug: non-selective Non steroidal anti inflammatory Drug
Sponsors: University of Dundee; University of Dundee; University of Glasgow; University of Nottingham
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy; Drug: prednisone
Sponsors: University of Alabama at Birmingham; Gary Cutter, PhD; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012
 |
Join Clinical Trials for Autoimmune Diseases - United Kingdom |
